<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01841489</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-339-0111</org_study_id>
    <nct_id>NCT01841489</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics</brief_title>
  <official_title>A Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, Open-Label, Adaptive Study of Novel GS-9973 Tablet Formulations to
      Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on
      GS-9973 Pharmacokinetics.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters for GS-9973</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>The primary outcome measure is the pharmacokinetic (PK) parameters for GS-9973 including AUC and Cmax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary pharmacokinetic parameters for GS-9973</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>A secondary outcome measure is the pharmacokinetic parameters for GS-9973 including Ctau and AUClast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>A secondary outcome measure is the safety and tolerability of GS-9973 which will be evaluated by the incidence of AEs including assessment of clinical laboratory test findings, physical examinations, 12-lead ECG abnormalities, and vital signs measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood PD parameters for GS-9973</measure>
    <time_frame>Up to 3 months</time_frame>
    <description>A secondary outcome measure is the blood pharmacodynamic parameters.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment A</intervention_name>
    <description>1600 mg GS-9973 (Formulation 1)</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment B</intervention_name>
    <description>1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole</description>
    <arm_group_label>Sequence 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment C</intervention_name>
    <description>1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine</description>
    <arm_group_label>Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment D</intervention_name>
    <description>1600 mg GS-9973 (Formulation 2)</description>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment E</intervention_name>
    <description>1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole</description>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment F</intervention_name>
    <description>1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine</description>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment G</intervention_name>
    <description>1600 mg GS-9973 (Reference formulation)</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment H</intervention_name>
    <description>1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)</description>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment I</intervention_name>
    <description>An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment J</intervention_name>
    <description>An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily</description>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have the ability to understand and sign a written informed consent form, which must be
             obtained prior to initiation of study procedures

          -  Must have a body mass index (BMI) range of approximately 19 to 30 kg/m2

          -  Must have a minimum weight of 45 kg

          -  Females of childbearing potential must have negative serum pregnancy tests at
             screening and baseline and must practice at least 1 reliable method of contraception
             as defined by the protocol

               -  Female subjects who utilize hormonal contraceptive as 1 of their birth control
                  methods must have used the same method for at least 3 months prior to study
                  dosing

          -  Male subjects must agree to use condoms during heterosexual intercourse and avoid
             sperm donation from Day -1 until 90 days following the last dose of study medication

          -  Must refrain from blood donation throughout the study period

          -  Must, in the opinion of the Investigator, be in good general

          -  Must be a non- or light smoker, eg, less than 10 cigarettes per day

        Exclusion Criteria:

          -  Pregnant or lactating subjects

          -  Use of prescribed or over-the-counter medications that affect gastric pH

          -  History of severe peptic ulcer disease, GERD, or other diseases requiring prolonged(&gt;6
             weeks) medication or surgical therapy to modify gastric pH

          -  Have a history of clinically significant cardiac abnormalities or presence of
             clinically significant abnormality on 12-lead ECG.

          -  Have a history of any cancer requiring systemic chemotherapy or radiation

          -  Have a history of bleeding disorders

          -  Have a history of liver disorders

          -  Current acute infection or history of acute infection within 7 days

          -  Have a recent history of alcohol or illicit drug abuse and/or have a positive test for
             selected drugs of abuse

          -  Have a positive hepatitis screen or positive Human Immunodeficiency Virus antibody
             test

          -  Have participated in another clinical trial within 28 days

          -  Have received transfusion of blood or plasma products within 6 months

          -  Have donated &gt; 500 mL blood within 56 days

          -  Are unable or unwilling to comply with study restrictions, return for follow-up
             appointments, or other considerations, which in the opinion of the Investigator, would
             make the candidate unsuitable for study participation

          -  Current or historical medical condition that is deemed to be of medical significance
             by the Investigator

          -  Have used prescription medications, over the counter products, herbal remedies and
             nutritional supplements within 7 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Hawkins, MD</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2013</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Lymphocytic Leukemia</keyword>
  <keyword>CLL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

